 Zai Lab Limited NASDAQ: ZLAB and Deciphera Pharmaceuticals, Inc. NASDAQ: DCPH today announced that the China National Medical Products Administration NMPA has accepted its New Drug Application NDA for ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumor GIST who have received prior treatment with 3 or more kinase inhibitors, including imatinib. Ripretinib was recently granted full approval by the U.S. Food and Drug Administration FDA for the treatment of fourth-line GIST. Ripretinib is also approved by Health Canada for the treatment of adult patients with advanced GIST who have received prior treatment with imatinib, sunitinib, and regorafenib and by the Australian Therapeutic Goods Administration for the treatment of adult patients with advanced GIST who have received prior treatment with 3 or more kinase inhibitors, including imatinib. 